CHICAGO (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

Walmart has become the latest store to halt sales of the popular heartburn treatment Zantac after health regulators warned about a potentially dangerous contaminant in the drug. The nation's largest ...

Feb 16 (Reuters) - Lawyers for a man who alleges he developed bladder cancer after taking GSK Plc's (GSK.L), opens new tab heartburn drug Zantac urged a California judge on Thursday to allow expert ...

In December, a federal judge dismissed 50,000 Zantac cases because the scientific evidence establishing cancer causation didn’t pass legal muster. In March, a California state judge reached the ...

A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making similar ...

The U.S. Food and Drug Administration announced Wednesday it is requesting manufacturers remove all prescription and over-the-counter ranitidine drugs from the market immediately. This is the latest ...

The drug Zantac can elevate the risk of a person developing cancer. The active ingredient, ranitidine, contains a contaminant called NDMA, which is a probable human carcinogen. The above information ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn ...

Shares of GSK, Sanofi and Haleon all sold off sharply this week amid investor fear over potential U.S. litigation charges focused on popular heartburn drug Zantac. This has been a known issue bumbling ...